To assess the efficacy and safety of combination therapy with clomiphene citrate (CC) and anastrozole (AZ) for male hypoandrogenism.
Introduction
Symptomatic hypoandrogenism affects an increasingly large number of men in the USA, with a reported prevalence of 5.6% for men aged 30-79 years [1] . While hypoandrogenism incidence increases with age, it can also present as infertility in younger men [2] . Exogenous testosterone has been used to increase serum testosterone levels and improve hypoandrogenism symptoms; however, this method usually results in negative feedback on the pituitary gland and further compromises fertility by decreasing intratesticular testosterone levels. High intratesticular testosterone levels are essential to maintain spermatogenesis and male fertility; furthermore, normal FSH and LH levels are necessary for optimal spermatogenesis [3] . Thus, treatment alternatives have evolved to increase testosterone levels by targeting endogenous testosterone production pathways [4] . Two drugs that are commonly used off-label in the treatment of male infertility are clomiphene citrate (CC) and anastrozole (AZ); however, data are lacking on the use of combination CC + AZ therapy to optimize the androgen axis of subfertile men, despite the fact that this is routinely employed by andrologists, as opposed to sole AZ therapy which can decrease oestradiol to undetectable levels, thus impairing bone health and sexual function [5, 6] .
Clomiphene citrate is a selective oestrogen receptor modulator that increases gonadotropin production at the hypothalamus-pituitary level, thus indirectly stimulating androgen synthesis [7] ; however, CC is associated with increased oestradiol levels and decreased testosterone: oestradiol ratio, which can limit CC dosing [8] . Low testosterone:oestradiol ratio may be a potentially treatable endocrinopathy in subfertile men [9] . Oestradiol suppresses gonadotropin secretion via negative feedback on the hypothalamus-pituitary axis, thus decreasing testosterone production and spermatogenesis; therefore, high oestradiol levels can contribute to male infertility [5] . Aromatase is a cytochrome P450 enzyme that converts testosterone to oestradiol and androstenedione to oestrone [10] . AZ is an aromatase inhibitor that decreases the conversion of testosterone to oestradiol. As a result of this mechanism, AZ produces a significantly higher testosterone:oestradiol ratio than CC [11] . Oligozoospermic men with hypoandrogenism and a low testosterone:oestradiol ratio had significantly improved endocrine and semen variables after treatment with AZ [12] . While both CC and AZ are used off-label for hypoandrogenism and/or male infertility, a recent randomized controlled trial showed that CC is more effective in increasing testosterone levels, while AZ was more effective in increasing the testosterone:oestradiol ratio [11] .
Combining CC and AZ therapies is an intuitive solution to optimize testosterone:oestradiol ratio while correcting low testosterone levels [13] . It has been suggested that up to 17% of patients on CC will eventually receive combination therapy with addition of AZ [14] ; however, no previous studies have investigated the efficacy and safety of CC + AZ combination therapy in hypoandrogenic men. Furthermore, such studies are unlikely to be conducted by pharmaceutical industries as these uses of CC and AZ are off-label uses of generic drugs and represent a relatively small market. The primary aim of the present study was to assess outcomes of combination CC and AZ therapy by monitoring hormone levels and side effects.
Materials and Methods
After obtaining institutional review board approval, we retrospectively reviewed the charts of hypoandrogenic subfertile men who visited our fertility clinic between 2014 and 2017. We included men who received combination therapy with oral CC and AZ for a period during their treatment. All the patients were seen and treated by a single male infertility specialist. Exclusion criteria were: history of any known sex chromosome disorders; recent exogenous testosterone or concomitant hormonal therapy; and lack of follow-up on combination therapy. CC dose varied from 25 to 100 mg daily to every other day and was titrated based on patients' response to treatment. AZ was added to CC if oestradiol levels were >50 pg/mL or testosterone:oestradiol ratio were <10 usually in presence of symptoms. AZ was usually started at 1 mg twice to thrice weekly and was titrated based on response to treatment.
Data on patient age, body mass index (BMI) and medical history were obtained. Baseline hypogonadism symptoms were measured using the Sexual Health Inventory for Men (SHIM) and Androgen Deficiency in Aging Male (ADAM) questionnaires. Laboratory values extracted at baseline included the following: LH, FSH, sex-hormone binding globulin (SHBG), albumin, total testosterone, bioavailable testosterone, oestradiol and testosterone:oestradiol ratio. Results of semen analyses were extracted when available. Morning total testosterone, bioavailable testosterone, oestradiol and testosterone:oestradiol ratio were also measured before combination therapy (CC only) and after starting the combination therapy (CC + AZ). Our follow-up protocol included measuring total testosterone, bioavailable testosterone and oestradiol levels at 3-4 weeks to assess initial response to treatment. If the patient remained on therapy for more than 3-6 months we also measured PSA and haematocrit in addition to total testosterone at the 3-6-month follow-up. Additional follow-ups included total testosterone, oestradiol, PSA, and haematocrit assessment every 6 months while on medications. Follow-up on combination therapy was categorized into <6 months (CC + AZ, follow-up 1) and ≥6 months (CC + AZ, follow-up 2). Side effects and adverse reactions to the medications were recorded.
Hypogonadism was defined as biochemical confirmation of low testosterone (a total testosterone level of <300 ng/dL or bioavailable testosterone of <155 ng/dL), accompanied by hypogonadal symptoms or a chief complaint of infertility (inability to conceive a child after 1 year in the absence of a known female factor). The presence of any of the following was considered a hypogonadal symptom: (i) positive ADAM questionnaire (a 'yes' answer to questions on decreased libido [Q1] or erectile dysfunction [Q7], or any other three questions); (ii) positive SHIM questionnaire (score <22); or (iii) a chief complaint of decreased libido or erectile dysfunction if ADAM/SHIM questionnaires were not completed. Bioavailable testosterone was calculated according to the Vermeulen formula [15] . Hyperoestrogenaemia was defined as oestradiol >50 pg/mL or a testosterone:oestradiol ratio of <10. The 2010 WHO [16] thresholds were used to define semen analysis abnormalities as follows: azoospermia, presence of no spermatozoa in the ejaculate; oligozoospermia, sperm concentration of <15 million/mL; asthenozoospermia, progressive motility <32%; teratozoospermia, <4% normal morphology on Kruger strict criteria. Haematocrit values >54% were considered abnormal [17] . We used an agespecific PSA threshold of 1.78 as the upper reference limit for patients aged 31-40 years [18] .
Variables are presented as median (25th-75th interquartile range [IQR]) or mean (SD) or mean (SE), as appropriate. A paired-sample t-test was used to compare pre-and posthormonal values according to a priori hypotheses to select the matched pairs (CC only vs baseline; CC + AZ follow-ups vs CC only). As a secondary aim, baseline and follow-up semen parameters were compared using Wilcoxon's signed-rank test. All statistical tests were two-sided and statistical significance was assessed at the 0.05 level. All analyses were performed using STATA 15 (Stata Corp, College Station, TX, USA).
Results
A total of 51 men with a mean (SD) age of 35.4 (7.4) years were included. The mean (SD) BMI was 35.0 (8.0) kg/m 2 . The baseline characteristics of the patients are shown in Table 1 . All patients were evaluated for male hypogonadism and were initially started on CC therapy. Treatment with CC significantly increased both total testosterone and bioavailable testosterone levels ( Fig. 1) . Mean (SE) oestradiol levels were also increased from 21.0 (1.4) pg/mL at baseline to 65.6 (3.3) pg/mL after CC-only treatment (P < 0.001; normal range: 10-50 pg/mL).
Anastrozole was added for hyperoestrogenaemia after a median (IQR) of 2.3 (1.1-4.4) months on CC treatment. The overall mean (SD) follow-up on combination therapy was 8.4 (7.4) months. Figure 1 shows the overall trends of hormone values at baseline and each follow-up. At first CC + AZ follow-up (mean [SD] 9.2 [4.4] weeks), oestradiol levels significantly decreased and testosterone:oestradiol ratio increased. There were no statistically significant changes in total testosterone or bioavailable testosterone after adding AZ (Table 2) . At the second CC + AZ follow-up (mean [SD] 32.4 [9.5] weeks), total testosterone, bioavailable testosterone, oestradiol and testosterone:oestradiol ratio all remained in the therapeutic range without significant changes compared with the first follow-up after starting AZ (Table 2) .
Overall, 11 patients (21.5%) experienced side effects on combination therapy that were attributable to one of the medications: five experienced anxiety or irritability; four reported decreased libido; and two had elevated (>54%) haematocrit levels. Four patients (8%) discontinued treatment because of side effects (anxiety/irritability, n = 1; decreased libido, n = 1; blurred vision, headache and increased haematocrit level, n = 1; asymptomatic increased haematocrit level, n = 1).
Twenty-eight patients had PSA levels measured during the follow-up and after at least 6 months on combination therapy. The mean (SE) PSA level was 1.36 (0.3) ng/mL and the median (IQR) was 0.6 (0.5-1.1) ng/mL. Three patients had PSA values >1.78 ng/mL at some stage during the treatment period. One of these was a 59-year-old with PSA 4.4 ng/mL on combination therapy; he had a history of BPH (baseline PSA 6.6 ng/mL) and his PSA levels did not increase on the medications. The second patient was aged 47 years with elevated PSA levels up to 4.6 ng/mL on combination therapy. He had pyospermia and a negative prostate biopsy and was treated with antibiotics; treatment with CC and AZ was continued after obtaining the biopsy results. The third patient had increased PSA levels during the treatment, but was diagnosed with prostatitis and pyospermia; PSA levels dropped to 0.6 ng/mL after antibiotic treatment while continuing CC and AZ therapy.
The mean (SE) haematocrit level was 48.1% (0.7) at the latest follow-up. Two patients had elevated haematocrit values. One had a haematocrit level of 57.6% as well as headaches and blurred vision on medications; both drugs were discontinued (due to side effects and elevated haematocrit levels) and the patient underwent phlebotomy. The haematocrit levels dropped to 50% afterwards. The second patient had a haematocrit level of 54.9% without any symptoms or other side effects; the medications were discontinued for this patient.
Overall, 38 patients had semen analysis available at baseline; nine patients were azoospermic and 20 were oligozoospermic. Of the nine patients with sperm concentration >20 million/ mL (normozoospermia), six had teratozoospermia, one had asthenozoospermia, and two had both teratozoospermia and asthenozoospermia. Nineteen patients had semen analysis available both at baseline and after at least 3 months of CC + AZ combination therapy (normozoospermia, n = 5; oligozoospermia, n = 9; and azoospermia, n = 5). All five patients with normozoospermia at baseline were still normozoospermic at the follow-up semen analysis. Of the nine oligozoospermic patients at baseline, two were normozoospermic at follow-up and another patient was azoospermic; the other six remained oligozoospermic. Of the five azoospermic patients, one remained so, while two were oligozoospermic and another two were normozoospermic at their follow-up on combination therapy. Table 3 shows the comparison between semen variables at baseline and combination therapy follow-up for these 19 patients. Only Values are presented as mean (SD) unless otherwise specified. ADAM, Androgen Deficiency in Aging Male; BMI, body mass index; SHBG, sex-hormone binding globulin; SHIM, Sexual Health Inventory for Men.
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Discussion
To our knowledge, this is the first study on outcomes and safety of combination therapy with CC and AZ in men. Our results show that the addition of AZ to CC is an effective means to reduce oestradiol levels and normalize the testosterone:oestradiol ratio while maintaining total testosterone levels within the therapeutic range. Combination therapy was found to be safe and well tolerated in most patients. Median PSA levels were within the normal agespecific limits. We recommend monitoring haematocrit levels both prior to and during treatment.
Management of idiopathic male infertility remains controversial, and empirical (off-label) medical therapies are commonly used [4] . A recent survey of urologists showed that~60% of respondents used empiric medical therapy in the treatment of idiopathic male infertility [19] . Two of the most commonly used medications are CC and AZ. CC indirectly increases androgen levels by stimulating GnRH production at the hypothalamus [7] . The resulting increases in testosterone, LH and FSH make CC an effective treatment for hypoandrogenism [11, 20, 21] . The increases in LH and FSH are major advantages over exogenous testosterone therapy, which results in LH and FSH suppression [22] ; however, elevations in oestradiol levels can occur after CC treatment [8] . This increase in oestradiol and decreased testosterone:oestradiol ratio can negatively affect fertility and spermatogenesis [9] . Our results support this rise in oestradiol levels, which significantly increased from 21.0 pg/mL at baseline to 65.6 pg/mL after CC-only treatment. This outcome was expected, as CC stimulates hypothalamic GnRH production.
Aromatase converts testosterone to oestradiol, which then exerts an inhibitory effect on Leydig and Sertoli cells [5] . AZ is an aromatase inhibitor, and thus will increase both testosterone level and the testosterone:oestradiol ratio [23] . Treatment with AZ in men with low testosterone:oestradiol ratios, can improve this ratio and also improve sperm variables [24] . It has been suggested that a low testosterone: oestradiol ratio, in combination with oligozoospermia and low testosterone level, represents a treatable endocrinopathy in subfertile men [9, 25] .
Patients with impaired testosterone:oestradiol ratios while undergoing treatment with tamoxifen (another selective oestrogen receptor modulator), have been shown to benefit from combined therapy with aromatase inhibitors [26] . Similarly, a recent study suggested that 17% of hypogonadal men on CC therapy later needed the addition of AZ to correct hyperoestrogenaemia [14] ; however, there is a lack of published evidence on the efficacy and safety of this combination. After the addition of AZ to CC in the present study, the testosterone:oestradiol ratio increased from 10.6 to 25.9; additionally, total testosterone and bioavailable testosterone levels remained in the target range. CC + AZ combination therapy could therefore be considered a viable approach to achieving a more robust response in testosterone levels while limiting the hyperoestrogenic effect of high-dose CC. Many of the men in the aforementioned study were obese (average BMI 35.1 kg/m 2 ), which was a similar finding in the present study (35 kg/m 2 ) [14] . Adipose tissue is an essential site of aromatase activity; thus aromatase expression correlates to body fat mass [27] . Studies on the correlation between BMI and hormonal levels and semen variables, however, have reported inconsistent data [28] . It has been suggested that obesity is associated with lower testosterone levels, higher oestradiol levels and lower testosterone: oestradiol ratio in men, which could be partly attributable to conversion of testosterone to oestradiol in adipose tissues. The higher oestradiol levels result in negative feedback on the hypothalamic-pituitary-gonadal axis, thus lowering testosterone levels [29] ; however, other mechanisms are probably involved, given the weak correlation between baseline BMI and oestradiol levels. Nevertheless, the association with BMI in the present study suggests that obese men may be more likely to develop hyperoestrogenaemia on CC monotherapy and may benefit from CC + AZ combination therapy, although future research is needed for confirmation. Additional studies should also seek to identify other groups of patients who would benefit from early addition of AZ.
The effect of CC or AZ on semen variables has been difficult to elucidate. This could be partly because of the poor association between hypoandrogenism and low sperm concentration [30] . In a randomized controlled trial comparing enclomiphene citrate (the trans isomer of CC) and topical testosterone, Kim et al. [31] suggested that CC could restore serum total testosterone and other hormonal values while maintaining sperm concentrations in obese hypogonadal men [31] . A double-blind trial of CC, however, found no improvements in semen variables compared with placebo in men with idiopathic infertility [32] . Another randomized trial comparing CC and AZ also found no significant improvements in semen variables compared with baseline in either treatment group [11] . The literature may not provide enough evidence to support using CC to improve [33] . Additionally, recent evidence suggests that long-term use of racemic CC, which is a mixture of enclomiphene and zuclomiphene isomers with different biological actions, leads to increased zuclomiphene concentrations which can potentially arrest spermatogenesis and limit the clinical effects of CC [34, 35] . Alternatively, other studies have shown that the use of aromatase inhibitors increases the testosterone:oestradiol ratio and can lead to improved sperm concentration and motility in oligozoospermic men [9] . Additional studies have shown that the use of AZ can improve semen variables in oligozoospermic men [23] [24] [25] . Our data fall somewhat in line with these results, with improvement only in semen concentration at follow-up after CC + AZ combination therapy. It is possible that the addition of AZ is correcting for the CC-induced decrease in testosterone:oestradiol ratio and subsequent decrease in semen variables. It is noteworthy that most men with baseline oligozoospermia in the present cohort also remained oligozoospermic on combination therapy; thus, our findings at best support the theory that combination therapy does not worsen semen variables; however, lack of consistent semen analyses at follow-ups, in addition to the small number of patients with semen data available, limits our conclusion in this regard.
Side effects common to exogenous testosterone supplementation include infertility and testicular atrophy, erythrocytosis, and possibly prostate-related events [36] . CC is a safer treatment for hypogonadism, as therapy avoids the polycythemia or prostate-related events seen in exogenous testosterone supplementation [20, 37, 38] . AZ is also an alternative that possesses fewer inherent adverse effects than exogenous testosterone [24] . The median PSA levels were within age-specific normal limits in the present study and there was no diagnosis of prostate cancer in our patients, which is consistent with the current literature [20] . The mean haematocrit level at follow-up was 48.2% and two patients experienced elevated (>54%) haematocrit levels, leading to discontinuation of the combination therapy. It should be noted, however, that our cohort might have higher baseline haematocrit as a result of the higher geographical altitude at which the study was conducted (1829 m) compared with the USA average (762 m) [20] . Nevertheless, we believe this finding merits attention and recommend checking haematocrit levels before and during treatment.
The present study has a number of strengths and limitations. To the best of our knowledge this is the first report on efficacy and safety of combination therapy with CC + AZ. The availability of baseline data as well as followups on CC and combination therapy allowed us to use each patient as his own control to provide a more robust comparison of changes in laboratory values; however, the retrospective design, small sample size, relatively short follow-up, and the possibility of selection bias limit our study findings. A homogenous patient population, younger patient age, and the geographical characteristics of our area, might also limit the generalizability of our findings. We did not use questionnaires to quantitatively assess symptom improvement in follow-ups; questionnaires such as the ADAM questionnaire are designed as screening tools for older men and have low specificity and thus are not validated as tools for follow-up symptom assessment [39] . In addition, the effect of dose adjustment and different regimens on hormonal changes cannot be elimiated; however, given the off-label use of these medication, there is no universal recommendation for dosing strength, and frequency of treatment is usually tailored based on patient response and achieving the clinical and hormonal goals. Lastly, the number of patients with pre-and post-semen analysis was limited in the present study and we were not able to compare semen variables at the CC follow-up with baseline and combination therapy follow-ups.
In conclusion, we found that AZ provided an effective means of lowering oestradiol levels and increasing the testosterone: oestradiol ratio after the initiation of CC therapy. Our results show that combination therapy is a safe approach with no effect on PSA levels. We recommend monitoring haematocrit levels both before and during treatment.
